Identification of potential drug targets by subtractive genome analysis of Escherichia coli O157:H7: An in silico approach

Advances and Applications in Bioinformatics and Chemistry

Volumn 8, Issue 1, 2015, Pages 49-63

  Mondal, Shakhinur Islam ^a,d   Ferdous, Sabiha ^a   Jewel, Nurnabi Azad ^a   Akter, Arzuba ^a,d   Mahmud, Zabed ^a   Islam, Md Muzahidul ^a   Afrin, Tanzila ^b   Karim, Nurul ^c,d  

^a SHAHJALAL UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Bangladesh)

^b EAST WEST UNIVERSITY   (Bangladesh)

^c JAHANGIRNAGAR UNIVERSITY   (Bangladesh)

^d UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

DNA polymerase III alpha; E. coli O157:H7; Homology modeling; KEGG metabolic pathways; Novel and broad spectrum antibiotic targets

Indexed keywords

EID: 84954205870     PISSN: None     EISSN: 11786949     Source Type: Journal    
DOI: 10.2147/AABC.S88522     Document Type: Article

References (91)

1. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol. 2004;2(2):123-140.
2. Law D. Virulence factors of Escherichia coli O157 and other Shiga toxin-producing E. coli. J Appl Microbiol. 2000;88(5):729-745.
3. Ostroff SM, Griffin PM, Tauxe RV, et al. A statewide outbreak of Escherichia coli O157:H7 infections in Washington State. Am J Epidemiol. 1990;132(2):239-247.
4. Griffin PM, Tauxe RV. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev. 1991;13:60-98.
5. Besser RE, Lett SM, Weber JT, et al. An outbreak of diarrhea and hemolytic uremic syndrome from Escherichia coli O157:H7 in fresh-pressed apple cider. JAMA. 1993;269(17):2217-2220.
6. Michino H, Araki K, Minami S, et al. Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakai City, Japan, associated with consumption of white radish sprouts. Am J Epidemiol. 1999; 150(8):787-796.
7. Hayashi T, Makino K, Ohnishi M, et al. Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res. 2001;8(1):11-22.
8. Walterspiel JN, Ashkenazi S, Morrow AL, Cleary TG. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection. 1992;20(1):25-29.
9. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000;342(26):1930-1936.
10. Mora A, Blanco JE, Blanco M, et al. Antimicrobial resistance of Shiga toxin (verotoxin)-producing Escherichia coli O157:H7 and non-O157 strains isolated from humans, cattle, sheep and food in Spain. Res Microbiol. 2005;156(7):793-806.
11. Meng J, Zhao S, Doyle MP, Joseph SW. Antibiotic resistance of Escherichia coli O157:H7 and O157:NM isolated from animals, food, and humans. J Food Prot. 1998;61(11):1511-1514.
12. Wilkerson C, Samadpour M, van Kirk N, Roberts MC. Antibiotic resistance and distribution of tetracycline resistance genes in Escherichia coli O157:H7 isolates from humans and bovines. Antimicrob Agents Chemother. 2004;48(3):1066-1067.
13. Kim HH, Samadpour M, Grimm L, et al. Characteristics of antibiotic-resistant Escherichia coli O157:H7 in Washington State, 1984-1991. J Infect Dis. 1994;170(6):1606-1609.
14. Schroeder CM, Zhao C, DebRoy C, et al. Antimicrobial resistance of Escherichia coli O157 isolated from humans, cattle, swine, and food. Appl Environ Microbiol. 2002;68(2):576-581.
15. Chan JN, Nislow C, Emili A. Recent advances and method development for drug target identification. Trends Pharmacol Sci. 2010;31(2): 82-88.
16. Allsop AE. Bacterial genome sequencing and drug discovery. Curr Opin Biotechnol. 1998;9(6):637-642.
17. Stumm G, Russ A, Nehls M. Deductive genomics: a functional approach to identify innovative drug targets in the post-genome era. Am J Pharmacogenomics. 2002;2(4):263-271.
18. Damte D, Suh JW, Lee SJ, Yohannes SB, Hossain MA, Park SC. Putative drug and vaccine target protein identification using comparative genomic analysis of KEGG annotated metabolic pathways of Mycoplasma hyopneumoniae. Genomics. 2013;102(1):47-56.
19. Amineni U, Pradhan D, Marisetty H. In silico identification of common putative drug targets in Leptospira interrogans. J Chem Biol. 2010;3(4): 165-173.
20. Barh D, Kumar A. In silico identification of candidate drug and vaccine targets from various pathways in Neisseria gonorrhoeae. In Silico Biol. 2009;9(4):225-231.
21. Oany AR, Emran AA, Jyoti TP. Design of an epitope-based peptide vaccine against spike protein of human coronavirus: an in silico approach. Drug Des Devel Ther. 2014;8:1139-1149.
22. Rahman MA, Noore MS, Hasan MA, et al. Identification of potential drug targets by subtractive genome analysis of Bacillus anthracis A0248: An in silico approach. Comput Biol Chem. 2014;52:66-72.
23. Galperin MY, Koonin EV. Searching for drug targets in microbial genomes. Curr Opin Biotechnol. 1999;10(6):571-578.
24. Tatusov RL, Koonin EV, Lipman DJ. A genomic perspective on protein families. Science. 1997;278(5338):631-637.
25. Koonin EV, Tatusov RL, Galperin MY. Beyond complete genomes: from sequence to structure and function. Curr Opin Struct Biol. 1998; 8(3):355-363.
26. Kobayashi K, Ehrlich SD, Albertini A, et al. Essential Bacillus subtilis genes. Proc Natl Acad Sci U S A. 2003;100(8):4678-4683.
27. Lavecchia A, Di Giovanni C. Virtual screening strategies in drug discovery: a critical review. Curr Med Chem. 2013;20(23): 2839-2860.
28. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 2006; 34(Database issue):D354-D357.
29. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010;38(Database issue): D355-D360.
30. Magrane M, Consortium U. UniProt Knowledgebase: a hub of integrated protein data. Database (Oxford). 2011;2011:bar009.
31. Zhang R, Lin Y. DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes. Nucleic Acids Res. 2009;37(Database issue): D455-D458.
32. Yu NY Wagner JR, Laird MR, et al. PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics. 2010;26(13):1608-1615.
33. Aguero F, Al-Lazikani B, Aslett M, et al. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov. 2008;7(11):900-907.
34. Butt AM, Nasrullah I, Tahir S, Tong Y. Comparative genomics analysis of Mycobacterium ulcerans for the identification of putative essential genes and therapeutic candidates. PLoS One. 2012;7(8):e43080.
35. Ren J, Xie L, Li WW, Bourne PE. SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison. Nucleic Acids Res. 2010;38(Web Server issue):W441-W444.
36. Cheng AC, Coleman RG, Smyth KT, et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol. 2007;25(1):71-75.
37. Keller TH, Pichota A, Yin Z. A practical view of 'druggability'. Curr Opin Chem Biol. 2006;10(4):357-361.
38. Holman AG, Davis PJ, Foster JM, Carlow CK, Kumar S. Computational prediction of essential genes in an unculturable endosymbiotic bacterium, Wolbachia of Brugia malayi. BMC Microbiol. 2009;9:243.
39. Knox C, Law V, Jewison T, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011; 39(Database issue):D1035-D1041.
40. Hecker N, Ahmed J, von Eichborn J, et al. SuperTarget goes quantitative: update on drug-target interactions. Nucleic Acids Res. 2012;40(Database issue):D1113-D1117.
41. Zhu F, Shi Z, Qin C, et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012;40(Database issue):D1128-D1136.
42. Gillespie JJ, Wattam AR, Cammer SA, et al. PATRIC: the comprehensive bacterial bioinformatics resource with a focus on human pathogenic species. Infect Immun. 2011;79(11):4286-4298.
43. Lambert C, Leonard N, De Bolle X, Depiereux E. ESyPred3D: Prediction of proteins 3D structures. Bioinformatics. 2002;18(9):1250-1256.
44. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006;22(2):195-201.
45. Melo F, Feytmans E. Assessing protein structures with a non-local atomic interaction energy. J Mol Biol. 1998;277(5):1141-1152.
46. Laskowski RA MacArthur M, Moss DS, Thornton JM. PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Cryst. 1993;26:283-291.
47. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997;18(15):2714-2723.
48. Binkowski TA, Naghibzadeh S, Liang J. CASTp: Computed Atlas of Surface Topography of proteins. Nucleic Acids Res. 2003;31(13): 3352-3355.
49. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007;35(Database issue):D198-D201.
50. Alland C, Moreews F, Boens D, et al. RPBS: a web resource for structural bioinformatics. Nucleic Acids Res. 2005;33(Web Server issue):W44-W49.
51. Sakharkar KR, Sakharkar MK, Chow VT. A novel genomics approach for the identification of drug targets in pathogens, with special reference to Pseudomonas aeruginosa. In silico Biol. 2004;4(3):355-360.
52. Chong CE, Lim BS, Nathan S, Mohamed R. In silico analysis of Burkholderia pseudomallei genome sequence for potential drug targets. In Silico Biol. 2006;6(4):341-346.
53. Duffield M, Cooper I, McAlister E, Bayliss M, Ford D, Oyston P. Predicting conserved essential genes in bacteria: in silico identification of putative drug targets. Mol Biosyst. 2010;6(12):2482-2489.
54. Caffrey CR, Rohwer A, Oellien F, et al. A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. PLoS One. 2009;4(2):e4413.
55. Heinrichs DE, Yethon JA, Whitfield C. Molecular basis for structural diversity in the core regions of the lipopolysaccharides of Escherichia coli and Salmonella enterica. Mol Microbiol. 1998;30(2):221-232.
56. Raetz CR, Guan Z, Ingram BO, et al. Discovery of new biosynthetic pathways: the lipid A story. J Lipid Res. 2009;50 Suppl:S103-S108.
57. Navarre WW, Schneewind O. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev. 1999;63(1):174-229.
58. Theisen AR, Murrell JC. Facultative methanotrophs revisited. J Bacteriol. 2005;187(13):4303-4305.
59. Welander PV, Metcalf WW. Loss of the mtr operon in Methanosarcina blocks growth on methanol, but not methanogenesis, and reveals an unknown methanogenic pathway. Proc Natl Acad Sci U S A. 2005; 102(30):10664-10669.
60. Peregrin-Alvarez JM, Sanford C, Parkinson J. The conservation and evolutionary modularity of metabolism. Genome Biol. 2009;10(6):R63.
61. Cabello P, Roldan MD, Moreno-Vivian C. Nitrate reduction and the nitrogen cycle in archaea. Microbiology. 2004;150(Pt 11):3527-3546.
62. Brondijk TH, Nilavongse A, Filenko N, Richardson DJ, Cole JA. NapGH components of the periplasmic nitrate reductase of Escherichia coli K-12: location, topology and physiological roles in quinol oxidation and redox balancing. Biochem J. 2004;379(Pt 1):47-55.
63. Kostakioti M, Newman CL, Thanassi DG, Stathopoulos C. Mechanisms of protein export across the bacterial outer membrane. J Bacteriol. 2005;187(13):4306-4314.
64. Kumamoto CA. Escherichia coli SecB protein associates with exported protein precursors in vivo. Proc Natl Acad Sci U S A. 1989;86(14): 5320-5324.
65. Dahl U, Jaeger T, Nguyen BT, Sattler JM, Mayer C. Identification of a phosphotransferase system of Escherichia coli required for growth on N-acetylmuramic acid. J Bacteriol. 2004;186(8):2385-2392.
66. Kotrba P, Inui M, Yukawa H. Bacterial phosphotransferase system (PTS) in carbohydrate uptake and control of carbon metabolism. J Biosci Bioeng. 2001;92(6):502-517.
67. Van Arnam JS, McMurry JL, Kihara M, Macnab RM. Analysis of an engineered Salmonella flagellar fusion protein, FliR-FlhB. J Bacteriol. 2004;186(8):2495-2498.
68. Macnab RM. How bacteria assemble flagella. Annu Rev Microbiol. 2003;57:77-100.
69. Yamamoto K, Hirao K, Oshima T, Aiba H, Utsumi R, Ishihama A. Functional characterization in vitro of all two-component signal transduction systems from Escherichia coli. J Biol Chem. 2005;280(2): 1448-1456.
70. Silakowski B, Kunze B, Nordsiek G, Blocker H, Hofle G, Muller R. The myxochelin iron transport regulon of the myxobacterium Stigmatella aurantiaca Sg a15. Eur J Biochem. 2000;267(21):6476-6485.
71. Rao CV, Ordal GW. The molecular basis of excitation and adaptation during chemotactic sensory transduction in bacteria. Contrib Microbiol. 2009;16:33-64.
72. White TA, Kell DB. Comparative genomic assessment of novel broad-spectrum targets for antibacterial drugs. Comp Funct Genomics. 2004;5(4):304-327.
73. Barh D Tiwari S, Jain N, Ali A, et al. In Silico Subtractive Genomics for Target Identification in Human Bacterial Pathogens. Drug Development Research. 2011;72: 162-177.
74. Chittori S, Savithri HS, Murthy MR. Structural and mechanistic investigations on Salmonella typhimurium acetate kinase (AckA): identification of a putative ligand binding pocket at the dimeric interface. BMC Struct Biol. 2012;12:24.
75. Lamers MH, Georgescu RE, Lee SG, O'Donnell M, Kuriyan J. Crystal structure of the catalytic α subunit of E. coli replicative DNA polymerase III. Cell. 2006;126(5):881-892.
76. Jain S, Gaind R, Gupta KB, et al. Yokenella regensburgei infection in India mimicking enteric fever. J Med Microbiol. 2013;62(Pt 6): 935-939.
77. Sarria JC, Vidal AM, Kimbrough RC. Infections caused by Kluyvera species in humans. Clin Infect Dis. 2001;33(7):E69-E74.
78. Ridell J, Siitonen A, Paulin L, Mattila L, Korkeala H, Albert MJ. Hafnia alvei in stool specimens from patients with diarrhea and healthy controls. J Clin Microbiol. 1994;32(9):2335-2337.
79. Palaniswamy C, Selvaraj DR, Selvaraj T. Gangrenous cholecystitis caused by Hafnia alvei: a case report and review of literature. J Am Med Dir Assoc. 2009;10(5):361-363.
80. Hassan S, Amer S, Mittal C, Sharma R. Ewingella americana: an emerging true pathogen. Case Rep Infect Dis. 2012;2012:730720.
81. Bayir O, Yildirim GA, Saylam G, Yuksel E, Ozdek A, Korkmaz MH. Atrophic rhinitis caused by Cedecea davisae with accompanying mucocele. Kulak Burun Bogaz Ihtis Derg. 2015;25(4):249-253.
82. Lamers MH, Georgescu RE, Lee SG, O'Donnell M, Kuriyan J. Crystal structure of the catalytic alpha subunit of E. coli replicative DNA polymerase III. Cell. 2006;126(5):881-892.
83. Pritchard AE, McHenry CS. Identification of the acidic residues in the active site of DNA polymerase III. J Mol Biol. 1999;285(3): 1067-1080.
84. Butler MM, Lamarr WA, Foster KA, et al. Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob Agents Chemother. 2007;51(1):119-127.
85. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.
86. Zhao YH, Le J, Abraham MH, et al. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci. 2001;90(6):749-784.
87. Rothwell PJ, Waksman G. Structure and mechanism of DNA polymerases. Adv Protein Chem. 2005;71:401-440.
88. Kelman Z, O'Donnell M. DNA polymerase III holoenzyme: structure and function of a chromosomal replicating machine. Annu Rev Biochem. 1995;64(1):171-200.
89. McCauley MJ, Shokri L, Sefcikova J, Venclovas C, Beuning PJ, Williams MC. Distinct double-and single-stranded DNA binding of E. coli replicative DNA polymerase III α subunit. ACS Chem Biol. 2008;3(9):577-587.
90. Barnes MH, Leo CJ, Brown NC. DNA polymerase III of Gram-positive eubacteria is a zinc metalloprotein conserving an essential finger-like domain. Biochemistry. 1998;37(44):15254-15260.
91. Jadaun A, Sudhakar DR, Subbarao N, Dixit A. In Silico Screening for Novel Inhibitors of DNA Polymerase III Alpha Subunit of Mycobacterium tuberculosis (Mtb DnaE2, H 37 R v). 2015;10(3):e0119760.